Valerio Therapeutics (XPAR:ALVIO) Research & Development: €0.58 Mil (TTM As of Dec. 2025)


XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
25 GF Score
Price €0.51
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics Research & Development?

Valerio Therapeutics XPAR:ALVIO +37.84% 25 Research & Development is €0.58 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVIO with a GF Score™ of 25/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Valerio Therapeutics's Research & Development for the six months ended in Dec. 2025 was €0.18 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.58 Mil.

Valerio Therapeutics  (XPAR:ALVIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Valerio Therapeutics Research & Development Related Terms

Valerio Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Valerio Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valerio Therapeutics Research & Development Chart

Valerio Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 7.87 9.68 5.14 0.58

Valerio Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.04 4.36 0.78 0.40 0.18
XPAR:ALVIO
25GF Score
Valerio Therapeutics XPAR:ALVIO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valerio Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.58 Mil mean?
Valerio Therapeutics (XPAR:ALVIO) has a Research & Development of €0.58 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Valerio Therapeutics and its competitors.
Is Valerio Therapeutics' Research & Development too high?
Valerio Therapeutics' current Research & Development is €0.58 Mil. Overall, Valerio Therapeutics has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Research & Development compare to VRTX and REGN?
Valerio Therapeutics' Research & Development of €0.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current Research & Development is €0.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.51 — trading 628.6% above its estimated fair value. The current Research & Development is €0.58 Mil. Valerio Therapeutics' overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Research & Development is €0.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Research & Development: €0.58 Mil
  • GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
  • GF Score™: 25/100 with 9 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
25GF Score

Get the complete analysis for XPAR:ALVIO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.07
GF Value